Neuphoria Therapeutics Inc. (NEUP)Healthcare | Biotechnology | Burlington, United States | NasdaqGM
4.77 USD
+0.05
(1.059%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.64 -0.13 (-0.130%) ⇩ (April 17, 2026, 4:53 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:07 p.m. EDT
The stock faces severe near-term headwinds following publicized failures in its anxiety drug trials (SAD Program) which likely triggered the recent plunge from ~$21 to current levels. While the balance sheet is currently fortress-strong with minimal debt and a high current ratio, providing a lengthy runway to pursue strategic alternatives, the fundamental catalyst for long-term recovery is unproven. With no dividend policy, negative earnings, and a lack of analyst coverage, this is a pure turnaround play fraught with risk rather than a value investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.076621 |
| AutoARIMA | 0.076621 |
| MSTL | 0.078276 |
| AutoTheta | 0.117487 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 8.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.138 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.113 |
| Revenue per Share | 5.765 |
| Market Cap | 25,714,570 |
| Forward P/E | -1.24 |
| Profit Margins | -37.79% |
| Previous Name | Bionomics Limited |
| Website | https://www.neuphoriatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.082692325 |
| Address1 | 100 Summit Drive |
| All Time High | 264.0 |
| All Time Low | 2.124 |
| Ask | 4.72 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 47,690 |
| Average Daily Volume3 Month | 48,380 |
| Average Volume | 48,380 |
| Average Volume10Days | 47,690 |
| Bid | 4.61 |
| Bid Size | 1 |
| Book Value | 5.523 |
| City | Burlington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.77 |
| Current Ratio | 9.043 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.8 |
| Day Low | 4.62 |
| Debt To Equity | 0.113 |
| Display Name | Neuphoria Therapeutics |
| Earnings Timestamp End | 1,742,212,800 |
| Earnings Timestamp Start | 1,741,863,540 |
| Ebitda | -1,199,915 |
| Ebitda Margins | -0.08007 |
| Enterprise To Ebitda | -2.982 |
| Enterprise To Revenue | 0.239 |
| Enterprise Value | 3,577,620 |
| Eps Current Year | -4.07 |
| Eps Forward | -3.845 |
| Eps Trailing Twelve Months | -0.69 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.3962 |
| Fifty Day Average Change | 0.3737998 |
| Fifty Day Average Change Percent | 0.08502793 |
| Fifty Two Week Change Percent | -8.269233 |
| Fifty Two Week High | 21.4 |
| Fifty Two Week High Change | -16.63 |
| Fifty Two Week High Change Percent | -0.77710277 |
| Fifty Two Week Low | 3.645 |
| Fifty Two Week Low Change | 1.125 |
| Fifty Two Week Low Change Percent | 0.30864197 |
| Fifty Two Week Range | 3.645 - 21.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,639,665,000,000 |
| Float Shares | 4,173,038 |
| Forward Eps | -3.845 |
| Forward P E | -1.2405722 |
| Free Cashflow | -803,346 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 14,986,733 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07723 |
| Held Percent Institutions | 0.49758 |
| Implied Shares Outstanding | 5,390,895 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.bionomics.com.au/page.php?section=34 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,734,998,400 |
| Last Split Factor | 1:12 |
| Long Business Summary | Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts. |
| Long Name | Neuphoria Therapeutics Inc. |
| Market | us_market |
| Market Cap | 25,714,570 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_3331473 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -5,663,908 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 25,768,478 |
| Number Of Analyst Opinions | 3 |
| Open | 4.73 |
| Operating Cashflow | -2,362,084 |
| Operating Margins | -0.124280006 |
| Payout Ratio | 0.0 |
| Phone | 781 439 5551 |
| Post Market Change | -0.12989998 |
| Post Market Change Percent | -2.72327 |
| Post Market Price | 4.6401 |
| Post Market Time | 1,776,459,224 |
| Prev Name | Bionomics Limited |
| Previous Close | 4.72 |
| Price Eps Current Year | -1.1719902 |
| Price Hint | 4 |
| Price To Book | 0.8636611 |
| Price To Sales Trailing12 Months | 1.7158222 |
| Profit Margins | -0.37793 |
| Quick Ratio | 8.762 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0500002 |
| Regular Market Change Percent | 1.05933 |
| Regular Market Day High | 4.8 |
| Regular Market Day Low | 4.62 |
| Regular Market Day Range | 4.62 - 4.8 |
| Regular Market Open | 4.73 |
| Regular Market Previous Close | 4.72 |
| Regular Market Price | 4.77 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 39,179 |
| Return On Assets | -0.04251 |
| Return On Equity | -0.26072 |
| Revenue Per Share | 5.765 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,390,895 |
| Shares Percent Shares Out | 0.005 |
| Shares Short | 26,849 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 14,323 |
| Short Name | Neuphoria Therapeutics Inc. |
| Short Percent Of Float | 0.005 |
| Short Ratio | 0.39 |
| Source Interval | 15 |
| State | MA |
| Symbol | NEUP |
| Target High Price | 20.0 |
| Target Low Price | 2.3 |
| Target Mean Price | 9.76667 |
| Target Median Price | 7.0 |
| Total Cash | 22,170,414 |
| Total Cash Per Share | 4.113 |
| Total Debt | 33,465 |
| Total Revenue | 14,986,733 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.69 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.77396 |
| Two Hundred Day Average Change | -2.0039601 |
| Two Hundred Day Average Change Percent | -0.29583287 |
| Type Disp | Equity |
| Volume | 39,179 |
| Website | https://www.neuphoriatx.com |
| Zip | 1,803 |